DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Dynavax Technologies Corporation (DVAX)
« Back to company indexDVAX Chatter Timeline
Stock Ticker for DVAX
Most Active Tweeters for DVAX
| User | Tweets |
|---|---|
| @Tickeron | 12 |
| @AmericanBanking | 5 |
| @Gambiste1 | 4 |
| @bbnsnews | 3 |
| @TheMarketsDaily | 3 |
Recent Tweets for DVAX
 |
@marketdollqueen $DVAX cmon...let it go already...don’t be squashing all the momo.... December 6th 2019, 1:12pm |
 |
@AmericanBanking Dynavax Technologies $DVAX Earns “Buy” Rating from William Blair https://t.co/0CT2tVwkFJ #stocks December 6th 2019, 12:12pm |
|
@AmericanBanking William Blair Equities Analysts Decrease Earnings Estimates for Dynavax Technologies Co. $DVAX https://t.co/lYH3sCha8l #stocks December 6th 2019, 7:12am |
 |
@bbnsnews Dynavax Technologies Co. Expected to Post FY2020 Earnings of -$1.10 Per Share $DVAX https://t.co/wt7Bt5L936 December 6th 2019, 7:12am |
 |
@dakotafinancial Dynavax Technologies $DVAX Stock Rating Upgraded by Zacks Investment Research https://t.co/PI8oy8mIKD December 6th 2019, 3:12am |
 |
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/3r4ZT0dLNL December 6th 2019, 1:12am |
 |
@EnterpriseLeade Dynavax Technologies Co. $DVAX Given Average Rating of “Buy” by Brokerages https://t.co/cv6NvBQlpA December 5th 2019, 11:12pm |
 |
@TheMarketsDaily Dynavax Technologies Co. $DVAX Given Consensus Rating of “Buy” by Brokerages https://t.co/ds6gIB4ZWV December 5th 2019, 11:12pm |
 |
@MaisaCorp $DVAX it has partnered with Albertsons Companies to provide Heplisav-B, a hepatitis B vaccine, to patients with a s… https://t.co/CJBflUS3w9 December 5th 2019, 7:12pm |
 |
@newsfilterio Dynavax up 4% premarket on Albertsons' deal in hepatitis B $DVAX https://t.co/7qn9DHIyOT December 5th 2019, 1:12pm |
 |
@TranscriptDaily Dynavax Technologies $DVAX Upgraded to “Hold” by Zacks Investment Research https://t.co/BSeCx8tU8c December 5th 2019, 12:12pm |
|
@EnterpriseLeade Dynavax Technologies $DVAX Lifted to Hold at Zacks Investment Research https://t.co/D3HIb7YgWW December 5th 2019, 12:12pm |
 |
@Gambiste1 RT @mb_willoughby: $dvax nice daily chart looking to breakout https://t.co/2IncDmnEbz December 5th 2019, 10:12am |
 |
@mb_willoughby $dvax nice daily chart looking to breakout https://t.co/2IncDmnEbz December 5th 2019, 10:12am |
 |
@StckPro $DVAX NEW ARTICLE : Dynavax up 4% premarket on Albertsons' deal in hepatitis B https://t.co/UL3DqCAqoj Get all the… https://t.co/qnvvlLPSR1 December 5th 2019, 8:12am |
 |
@MarketCurrents $DVAX - Dynavax up 4% premarket on Albertsons' deal in hepatitis B https://t.co/fSSVgTUO93 December 5th 2019, 8:12am |
|
@bbnsnews Brokerages Expect Dynavax Technologies Co. $DVAX Will Announce Quarterly Sales of $11.92 Million https://t.co/7J79OCBRLS December 5th 2019, 12:12am |
 |
@ConsumerFeed $11.92 Million in Sales Expected for Dynavax Technologies Co. $DVAX This Quarter https://t.co/P16iELE8lg December 5th 2019, 12:12am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/vkFsPNGzQL December 4th 2019, 10:12pm |
|
@MaisaCorp $DVAX Announces Heplisav-B Post-Marketing Requirement Interim Report Completed December 3rd 2019, 6:12pm |
|
@TranscriptDaily Dynavax Technologies Co. $DVAX Receives $16.50 Consensus PT from Analysts https://t.co/qXqOfaJ3IV December 3rd 2019, 2:12pm |
 |
@stocknewstimes Dynavax Technologies Co. $DVAX Receives $16.50 Average Price Target from Brokerages https://t.co/jhvHX9phJE December 3rd 2019, 2:12pm |
 |
@JUDDLILIHA RT @bradloncar: $DVAX finished up an interim analysis of the post-marketing follow-up of HEPLISAV-B and says there were no imbalances in AM… December 3rd 2019, 12:12pm |
 |
@Briefingcom $DVAX: Dynavax files report on cumulative analysis of post-marketing study of HEPLISAV-B for review by the FDA https://t.co/c6ns2IO271 December 3rd 2019, 9:12am |
 |
@gregorypozo RT @OpenOutcrier: $DVAX (+3.1% pre) Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed - GN https://t.co/9eU… December 3rd 2019, 9:12am |
 |
@OpenOutcrier $DVAX (+3.1% pre) Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed - GN https://t.co/9eUgUV1iO9 December 3rd 2019, 8:12am |
 |
@AlpBugraBasat @avidresearch In particular, vaccine R&D is more of a big pharm business these days. $DVAX is a unique example in that. December 3rd 2019, 7:12am |
|
@Gambiste1 RT @otcdynamics: $DVAX Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed https://t.co/TmkcaHC3VU December 3rd 2019, 7:12am |
|
@Gambiste1 RT @avidresearch: @AlpBugraBasat Poor $DVAX used every ounce of their energy to get Hep B vaccine approved. agree with what u said, I.e. st… December 3rd 2019, 7:12am |
 |
@otcdynamics $DVAX Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed https://t.co/TmkcaHC3VU December 3rd 2019, 7:12am |
 |
@bradloncar $DVAX finished up an interim analysis of the post-marketing follow-up of HEPLISAV-B and says there were no imbalances in AMI events. December 3rd 2019, 7:12am |
 |
@avidresearch @AlpBugraBasat Poor $DVAX used every ounce of their energy to get Hep B vaccine approved. agree with what u said, I… https://t.co/pl9anxerAs December 3rd 2019, 6:12am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/nKAJjxkdjZ December 3rd 2019, 12:12am |
 |
@dispatchtribune $11.92 Million in Sales Expected for Dynavax Technologies Co. $DVAX This Quarter https://t.co/ygKaQ4VUOM December 2nd 2019, 9:12pm |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/tkGP2Ma5nE December 2nd 2019, 4:12am |
|
@dakotafinancial Dynavax Technologies $DVAX Lifted to “Hold” at Zacks Investment Research https://t.co/JdQ4euo68C December 2nd 2019, 3:12am |
 |
@ChartMill $DVAX has an average volume of 1117020. This is a good sign as it is always nice to have a liquid stock.… https://t.co/YuvIubUbGy December 1st 2019, 2:12pm |
 |
@WeekHerald Zacks Investment Research Upgrades Dynavax Technologies $DVAX to Hold https://t.co/eAbdXGJKx8 December 1st 2019, 7:12am |
 |
@OlympiaReport Dynavax Technologies $DVAX Raised to “Hold” at Zacks Investment Research https://t.co/HTVk3SitnR December 1st 2019, 7:12am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/5Co4zi3acw December 1st 2019, 6:12am |
|
@bbnsnews Dynavax Technologies $DVAX Upgraded at Zacks Investment Research https://t.co/WPCRZEDSmc November 30th 2019, 1:11am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/1RWpKGiFga November 30th 2019, 12:11am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/ZJvBcdrDPM November 28th 2019, 11:11pm |
|
@TranscriptDaily Zacks Investment Research Upgrades Dynavax Technologies $DVAX to “Hold” https://t.co/GnA3pGioNO November 28th 2019, 10:11pm |
|
@TheMarketsDaily Zacks Investment Research Upgrades Dynavax Technologies $DVAX to “Hold” https://t.co/Yr3TwEj8Cw November 28th 2019, 10:11pm |
|
@stocknewstimes Zacks Investment Research Upgrades Dynavax Technologies $DVAX to “Hold” https://t.co/NPcfwR85T2 November 28th 2019, 9:11pm |
 |
@ThisLincolnian Zacks: Analysts Expect Dynavax Technologies Co. $DVAX to Announce -$0.34 Earnings Per Share https://t.co/xWtIKbVlIg November 28th 2019, 9:11am |
|
@ThisLincolnian Dynavax Technologies Co. $DVAX Receives Average Recommendation of “Buy” from Brokerages https://t.co/WLjLAzTfrB November 28th 2019, 4:11am |
|
@AmericanBanking Dynavax Technologies Co. $DVAX Receives Average Recommendation of “Buy” from Brokerages https://t.co/pidBUy5DCw #stocks November 28th 2019, 4:11am |
|
@Tickeron $DVAX in Downtrend: RSI indicator exits overbought zone. View odds for this and other indicators:… https://t.co/npp8P1gB4N November 28th 2019, 12:11am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.